Hot Biotech Stocks To Own For 2019

News coverage about Aptevo Therapeutics (NASDAQ:APVO) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.6416303872564 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

Hot Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Max Byerly]

    Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

  • [By Logan Wallace]

    Eqis Capital Management Inc. grew its position in Amgen, Inc. (NASDAQ:AMGN) by 3.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 42,769 shares of the medical research company’s stock after acquiring an additional 1,361 shares during the period. Amgen accounts for approximately 0.5% of Eqis Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest position. Eqis Capital Management Inc.’s holdings in Amgen were worth $7,895,000 at the end of the most recent reporting period.

  • [By Keith Speights]

    It’s a big drugmaker with a blockbuster immunology drug as its top-selling product. It pays an attractive dividend. And it faces some uncertainties. This description fits Amgen (NASDAQ:AMGN), but it applies just as well to Johnson & Johnson (NYSE:JNJ).

  • [By Lee Jackson]

    This biotech giant remains a top stock for investors to buy and a safe way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN) has been a biotechnology pioneer since 1980 and has grown to be one of the world’s leading independent biotech companies. It has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

Hot Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Ethan Ryder]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

Hot Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Hot Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Russell Investments Group Ltd. boosted its holdings in Biogen (NASDAQ:BIIB) by 40.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 183,809 shares of the biotechnology company’s stock after buying an additional 52,654 shares during the period. Russell Investments Group Ltd.’s holdings in Biogen were worth $50,222,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released for IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By Shannon Jones]

    In this week’s episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte’s Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis’ (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stock’s 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

Leave a Reply

Your email address will not be published. Required fields are marked *